757251-39-1

Basic information

• Product Name: 4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLINAMIDE
• Synonyms: 4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLINAMIDE;2-Pyridinecarboxamide,4-(4-amino-3-fluorophenoxy)-N-methyl-;4-(4-Amino-3-fluorophenoxy)pyridine-2-carboxylic acid methylamide;4-(4-Amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide;4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYL-2-PYRIDINECARBOXAMIDE;4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide EINECS;4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLIMIDE;Regorafenib Intermediate
• CAS NO: 757251-39-1
• Molecular Formula: C₁₃H₁₂FN₃O₂
• Molecular Weight: 261.25
• EINECS: 1592732-453-0
• Product Categories: Regorafenib
• Mol File: 757251-39-1.mol
• Article Data: 37

Chemical Properties

• Melting Point: 143 °C
• Boiling Point: 459.8°C at 760 mmHg
• Flash Point: 231.9°C
• Appearance: /
• Density: 1.305
• Vapor Pressure: 1.22E-08mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Sparingly), Methanol (Slightly)
• PKA: 13.92±0.46(Predicted)
• Water Solubility: 190mg/L at 20℃
• CAS DataBase Reference: 4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLINAMIDE(757251-39-1)
• EPA Substance Registry System: 4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLINAMIDE(757251-39-1)

Safety Data

• Hazardous Substances Data: 757251-39-1(Hazardous Substances Data)

Usage

Uses

4-(4-Amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide is a compound used as a reagent to synthesize Regorafenib (R143000), a multikinase inhibitor that is used to treat patients with advanced colorectal cancer.

InChI:InChI=1/C13H12FN3O2/c1-16-13(18)12-7-9(4-5-17-12)19-8-2-3-11(15)10(14)6-8/h2-7H,15H2,1H3,(H,16,18)

Upstream product

• 882167-77-3 4-chloro-N-methyl-pyridine-2-carboxamide hydrochloride 
• 399-95-1 4-amino-3-fluorophenol 
• 108-10-1 4-methyl-2-pentanone 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 103842-00-8 N-(2-fluoro-4-hydroxyphenyl)acetamide 
• 176977-85-8 methyl 4-chloropyridine-2-carboxylate hydrochloride 
• 1209459-88-0 4-bromo-pyridine-2-carboxylic acid methyl amide 
• 5470-22-4 4-chloropicolinic acid 
• 67-56-1 methanol 
• 755037-03-7 regorafenib 
• 1493-27-2 ortho-nitrofluorobenzene 
• 372-20-3 3-fluorophenol 
• 51727-15-2 4-chloro-2-pyridine carboxylic acid chloride hydrochloride 
• 98-98-6 2-Picolinic acid 

Downstream Products

• 755037-03-7 regorafenib 
• 835621-08-4 4-{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide mesylate 
• 835621-07-3 4-{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide hydrochloride 
• 1036712-94-3 ethyl 3-(3-tert-butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)-pyridin-4-yl]oxy}phenyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzoate 

Relevant articles and documents

Synthesis method of regorafenib

The invention provides a synthesis method of regorafenib, which adopts 3-fluoro-4-nitrophenol as a raw material to replace the traditional 3-fluoro-4-aminophenol to carry out etherification reaction, and then carries out catalytic hydrogenation to obtain 4-(4-amino-3-fluorophenoxy)-N-methylpyridine-2-formamide, and has the advantages that the nitro stability is much higher than the amino stability; catalytic hydrogenation is carried out after etherification with the 4-chloro-2-pyridine formamide, such that the hydroxyl group is etherified so that the product stability is improved greatly, the purity and the yield of the product obtained after the catalytic hydrogenation are substantially improved, and the quality of the final product regorafenib is ensured. 3-fluorine-4-nitrophenol is used as a starting material to be subjected to etherification reaction with 4-chlorine-2-pyridine formamide, so that 4-methyl-2-pentanone is not needed to protect amino, and the quality of an intermediate obtained after catalytic hydrogenation and the quality of a final product are better.

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Substituted pyridine-2-formamide compound and application thereof

The invention belongs to the technical field of medicinal chemistry, and relates to a substituted pyridine-2-formamide compound and application thereof, wherein specifically the substituted pyridine-2-formamide compound has a structure represented by a formula I. According to the invention, based on excellent in vitro inhibition activity on VEGFR-2 kinase and PDGFR-beta kinase and HUVEC cell inhibition activity, the compound can be used as a small-molecular tyrosine kinase (especially Raf kinase) inhibitor, has the effect of inhibiting cell proliferation and angiogenesis, has good antitumor activity, and has a good effect of treating tumor diseases of mammals (including human beings).